Bio-Techne licenses antibody to Xencor

By The Science Advisory Board staff writers

Bio-Techne has licensed an antibody to Xencor for therapeutic development.

Bio-Techne gave access to the antibody for use with Xencor's proprietary XmAb protein engineering technology, which aims to develop new cancer therapeutics such as bispecific antibodies and engineered cytokines. This is Bio-Techne's third licensing agreement with Xencor, the firms said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking